Gender-specific symptom outcomes on cariprazine treatment: a 12-month naturalistic longitudinal follow-up study in schizophrenia
Frontiers in Psychiatry · 23.06.2026 · 17
DOI: 10.3389/fpsyt.2026.1795351 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Psychiatry, online erschienen am 23.06.2026. Verfasst von Claudia Carmassi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
A growing body of literature is focusing on third-generation antipsychotics and their unique characteristics, but few studies have examined gender as a crucial factor in response profiles. The present study aims to address this gap by analyzing the outcomes of 12-month naturalistic treatment with cariprazine to elucidate changes in specific psychopathological domains between men and women.
Methods
The present 12-month longitudinal naturalistic study involved a sample of individuals diagnosed with schizophrenia according to the DSM-5-TR treated with cariprazine at the outpatients’ psychiatric services of a major university and community hospitals in Italy. The assessments conducted included sociodemographic data, the Structured Clinical Interview for the DSM-5 (SCID-5), and the Positive and Negative Symptom Scale (PANSS) Total and Subscale scores, as well as the PANSS-derived Marder factors. The PANSS was administered at three time points: before starting the treatment with cariprazine (T0), after 6 months (T1), and after 12 months (T2).
Results
Fifteen male and 17 female subjects were assessed at the three time points. The mean dose of cariprazine was 4.2 ± 1.3 mg for men and 4.0 ± 1.5 mg for women. Both genders exhibited improvements in all PANSS subscale symptoms after 6 and 12 months of cariprazine treatment compared to the baseline, with the only exception of the Uncontrolled hostility/excitement Marder factor among men. Progressive improvements through time points in symptom subsca\les were found in both sexes, reaching numerical differences in every PANSS subscale in both sexes at T2. Gender specifc response profiles emerged after 6 and 12 months of treatment in the PANSS subscales and items in men and women.
Discussion
Cariprazine exhibited significant efficacy in both sexes, with no significant differences between men and women despite a gender specific response profile emerged. Additional studies are needed to further investigate the efficacy profile and long-term outcome of cariprazine treatment by gender.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- Department of Mental Health and Addiction, Azienda USL Toscana Nord-Ovest, Livorno, Italy.
- Department of Mental Health and Addiction, Azienda USL Toscana Nord-Ovest, Massa, Italy.
- Department of Mental Health and Addiction, Azienda USL Toscana Nord-Ovest, Lucca, Italy.
Zitieren
APA
Carmassi, C., Pedrinelli, V., Bordacchini, A., Rimoldi, B., Parrini, L., Bertelloni, C. A., & Dell'Oste, V. (2026). Gender-specific symptom outcomes on cariprazine treatment: a 12-month naturalistic longitudinal follow-up study in schizophrenia. Frontiers in Psychiatry, 17. https://doi.org/10.3389/fpsyt.2026.1795351
Vancouver
Carmassi C, Pedrinelli V, Bordacchini A, Rimoldi B, Parrini L, Bertelloni CA, et al. Gender-specific symptom outcomes on cariprazine treatment: a 12-month naturalistic longitudinal follow-up study in schizophrenia. Frontiers in Psychiatry. 2026;17. doi:10.3389/fpsyt.2026.1795351
BibTeX
@article{Carmassi2026,
author = {Carmassi, Claudia and Pedrinelli, Virginia and Bordacchini, Andrea and Rimoldi, Berenice and Parrini, Livia and Bertelloni, Carlo A and Dell'Oste, Valerio},
title = {Gender-specific symptom outcomes on cariprazine treatment: a 12-month naturalistic longitudinal follow-up study in schizophrenia},
journal = {Frontiers in Psychiatry},
year = {2026},
volume = {17},
doi = {10.3389/fpsyt.2026.1795351}
}
EUVIMED